Predictors of damage progression in portuguese patients with systemic lupus erythematosus

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 822-828

  Santos, Maria José ^a   Vinagre, Filipe ^b   Nero, Patrícia ^c,d   Barcelos, Filipe ^e   Barcelos, Anabela ^f   Rodrigues, Ana Maria ^g   De Matos, António Alves ^c,d   Silva, Cândida ^e   Miranda, Luis ^e   Capela, Susana ^g   Marques, Aurora ^g   Branco, Jaime ^c,d   Da Silva, José Canas ^a  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c HOSPITAL EGAS MONIZ   (Portugal)

^d NOVA MEDICAL SCHOOL   (Portugal)

^e INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^f Hospital Infante D Pedro EPE   (Portugal)

^g HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Organ damage; Outcome; Portugal; SLICC; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PHOSPHOLIPID ANTIBODY;

ADULT; CARDIOVASCULAR SYSTEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM; ORGAN INJURY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PORTUGAL; PREDICTION; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 69949134076     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04669.x     Document Type: Conference Paper

References (23)

1. Cervera, R., M. Abarca-Costalago, D. Abramovicz, et al. 2006. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project." Autoimmun. Rev. 5: 180-186. (Pubitemid 43234182)
2. Mok, C.C., L.Y. Ho, M.Y. Cheung, et al. 2008. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand. J. Rheumatol. 5: 1-7.
3. Wang, C., N.E. Mayo, P.R. Fortin & C. Wang. 2001. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J. Rheumatol. 28: 525-532.
4. Nossent, J., N. Cikes, E. Kiss, et al. 2007. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 16: 309-317.
5. Cardoso, C.R., F.V. Signorelli, J.A. Papi & G.F. Salles. 2008. Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. Lupus 17: 1042-1048.
6. Nived, O., A. Jönsen, A.A. Bengtsson, et al. 2002. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J. Rheumatol. 29: 1398-1400.
7. Alarcon, G.S., J.M. Roseman, J. McGwin, Jr., et al. 2004. Systemic lupus erythematosus in three ethnic groups.XX. Damage as a predictor of further damage. Rheumatology 43: 202-205.
8. Zonana-Nacach, A., A. Camargo-Coronel, P. Yáñez, et al. 1998. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 7: 119-123.
9. Gladman, D., M. Urowitz, P. Rahman, et al. 2003. Accrual of organ damage over time in patients with systemic lupus erythematosus. J. Rheumatol. 30: 1955-1959.
10. Molad, Y., A. Gorshtein, A.J. Wysenberg, et al. 2001. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11: 356-361.
11. Santos, M.J., S. Capela, R. Figueira, et al. 2007. Characterization of a Portuguese population with systemic lupus erythematosus. Acta. Rheumatol. Port. 32: 153-161.
12. Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725.
13. American Diabetes Association. 2004. Diagnosis and classification of diabetes mellitus. Diabetes Care 27: S5-S10.
14. Gladman, D., E. Ginzler, C. Goldsmith, et al. 1996. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 39: 363-369.
15. Cassano, G., S. Roverano, S. Paira, et al. 2007. Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study. Clin. Rheumatol. 26: 2017-2022.
16. Alarcon, G., G. McGwin, Jr., A.A. Bartolucci, et al. 2001. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum. 44: 2797-2806.
17. Hughes, G. 2008. Hughes Syndrome (the antiphos-pholipid syndrome): Ten clinical lessons. Autoimmun. Rev. 7: 262-266.
18. Prasad, R., D. Ibañez, D. Gladman & M. Urowitz. 2006. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 15: 285-291.
19. Ibanez, D., D. Gladman & M.B. Urowitz. 2005. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J. Rheumatol. 32: 824-827.
20. Stoll, T., N. Sutcliffe, J. Mach, et al. 2004. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology 43: 1039-1044.
21. Zonana-Nacach, A., S.G. Barr, L.S. Magder & M. Petri. 2000. Damage in systemic lupus erythemato-sus and its association with corticosteroids. Arthritis Rheum. 43: 1201-1808.
22. Toloza, S.M., A.G. Uribe & G. McGwin, Jr. 2004. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictorsofvas-cular events. Arthritis Rheum. 50: 3947-3957.
23. Colombo, B.M., F. Cacciapaglia, M. Puntoni, et al. 2008. Traditional and nontraditional risk factors in accelerated atherosclerosis in Systemic Lupus Ery-thematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun. Rev. [Epub ahead of print] doi: 10.1016/j.autrev.2008.10.002.